Quantitative evaluation of the medicine innovation policy in China: based on the PMC-Index model

被引:3
作者
Guo, Dan [1 ]
Qi, Liwen [1 ]
Song, Xiaoting [1 ]
机构
[1] Tongji Univ, Shanghai Int Coll Intellectual Property, Shanghai, Peoples R China
关键词
PMC-Index model; medicine innovation policy; China; quantitative evaluation; policy formulation; QUALITY-OF-LIFE; PHARMACEUTICAL POLICY; OUTCOMES; IMPACT;
D O I
10.3389/fpubh.2024.1403320
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Medicine innovation is crucial in promoting the sustainable development of medicine undertakings, which has significant economic and social benefits. China is the main force in global medicine consumption, with a huge demand for innovative medicines. Thus, the Chinese government releases a series of policies aimed at providing scientific and reasonable guidance for medicine innovation. However, there is inadequate quantitative evaluation and comparison of various medicine innovation policies in the existing studies.Methods This paper adopts the approach of text mining and the Policy Modeling Consistency Index (PMC-Index) model to construct an evaluation system and then quantitatively evaluates and compares the traditional Chinese medicine innovation policies (TCMIPs), the biological medicine innovation policies (BMIPs), and the multiple medicine innovation policies (MMIPs) in China.Results The results indicate that: (1) The three types of drug innovation policies have similarities in content and goal through comparative analysis of high-frequency words, while they also have their own characteristics. (2) The average PMC-Index of 29 TCMIPs is 5.77, which has the highest policy bad rate (21%); the average PMC-Index of 12 BMIPs is 6.21, which has the highest policy good rate (92%); moreover, the average PMC-Index of 35 MMIPs is 6.06, which has the highest policy excellence rate (26%). (3) The BMIPs, MMIPs, and TCMIPs have similar scores on policy object, policy orientation, policy timeliness, policy evaluation, and policy accessibility, while they differ significantly mainly on policy nature, incentive method, policy function, policy issuing agency, and policy instrument.Discussion This study contributes to a comprehensive understanding of medicine innovation policies in China, in order to provide theoretical support for future policy formulation and optimization in the medicine industry. Moreover, we expand the application scenarios of policy diffusion theory.
引用
收藏
页数:17
相关论文
共 72 条
  • [1] Assessment of factors affecting innovation policy in biotechnology
    Aghmiuni, Samira Khodi
    Siyal, Saeed
    Wang, Qiang
    Duan, Yuzhen
    [J]. JOURNAL OF INNOVATION & KNOWLEDGE, 2020, 5 (03): : 179 - 189
  • [2] EVALUATIVE RESEARCH - PRINCIPLES AND PRACTICE IN PUBLIC SERVICE AND SOCIAL ACTION PROGRAMS - SUCHMAN,EA
    BIGMAN, SK
    [J]. JOURNAL OF LEISURE RESEARCH, 1969, 1 (02) : 209 - 211
  • [3] A study of intellectual property protection policies and innovation in the Indian pharmaceutical industry and beyond
    Bouet, Dominique
    [J]. TECHNOVATION, 2015, 38 : 31 - 41
  • [4] Labor market policy evaluation in equilibrium: Some lessons of the job search and matching model
    Cahuc, Pierre
    Le Barbanchon, Thomas
    [J]. LABOUR ECONOMICS, 2010, 17 (01) : 196 - 205
  • [5] Analysis of Social Effects on Employment Promotion Policies for College Graduates Based on Data Mining for Online Use Review in China during the COVID-19 Pandemic
    Chen, Tinggui
    Rong, Jingtao
    Peng, Lijuan
    Yang, Jianjun
    Cong, Guodong
    Fang, Jing
    [J]. HEALTHCARE, 2021, 9 (07)
  • [6] Chen XX, 2022, LANCET, V400, P1967, DOI 10.1016/S0140-6736(22)01546-X
  • [7] Chen Y., 2023, China Reform, V1, P59
  • [8] The policy-making trend analysis of municipal solid waste in China 1980-2015
    Chu, Zhujie
    Wu, Boyi
    He, Zhiyong
    Zhuang, Jun
    Wang, Wenna
    [J]. WASTE MANAGEMENT & RESEARCH, 2019, 37 (06) : 601 - 610
  • [9] The impact of health insurance mandates on drug innovation: evidence from the United States
    Chun, Natalie
    Park, Minjung
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (02) : 323 - 344
  • [10] Human health benefits and burdens of a pharmaceutical treatment: Discussion of a conceptual integrated approach
    Debaveye, Sam
    De Soete, Wouter
    De Meester, Steven
    Vandijck, Dominique
    Heirman, Bert
    Kavanagh, Shane
    Dewulf, Jo
    [J]. ENVIRONMENTAL RESEARCH, 2016, 144 : 19 - 31